Senticell Raises $7M Seed for Red Blood Cell Diagnostics

Senticell has successfully closed a nearly $7 million seed funding round, significantly oversubscribed, to advance its novel liquid biopsy technology. This capital infusion, backed by prominent investors including The Venture City, Capital Factory, Scalpel Ventures, and Evoce Capital, alongside several private individuals, will accelerate the development of its unique diagnostic platform that leverages red blood cells.

The company's proprietary approach, exclusively licensed from the University of Pennsylvania, focuses on extracting and analyzing nucleic acids associated with red blood cells. This methodology is rooted in over a decade of pioneering research, notably involving Dr. Nilam Mangalmurti, a co-founder and the Chief Scientific Advisor at Senticell. The scientific premise suggests that red blood cells, the most abundant cells in the body with a long circulation time, offer a rich, previously underutilized reservoir of diagnostic information, potentially capturing signals missed by conventional plasma-based methods, especially in early-stage cancers.

This innovative strategy addresses a critical unmet need in oncology diagnostics. The global liquid biopsy market is projected to reach substantial figures, with various reports estimating growth to exceed $10 billion by the end of the decade, driven by the demand for less invasive and more accurate cancer detection. Senticell's focus on red blood cells positions it to potentially capture a unique segment of this expanding market, particularly for detecting minimal residual disease and early recurrence.

To rigorously validate its platform, Senticell is actively engaged in two prospective clinical studies in collaboration with Penn Medicine. The first study, involving approximately 200 patients diagnosed with lung and pancreatic cancers, aims to assess the detection of genetic markers prior to surgery and monitor for post-operative recurrence. This crucial research is anticipated to yield results by the first quarter of 2027.

A second study will encompass around 100 patients with head and neck and cervical cancers. This initiative will concentrate on evaluating minimal residual disease and post-treatment surveillance, with findings expected by the fourth quarter of 2026. These clinical validations are paramount for demonstrating the efficacy and broad applicability of Senticell's red blood cell-based diagnostic capabilities.

The substantial seed funding will be instrumental in supporting these ongoing oncology studies and further refining Senticell's technological infrastructure. This strategic investment is expected to propel the company toward significant advancements in early cancer detection and the broader field of personalized medicine, underscoring strong investor confidence in the scientific foundation and the leadership team's vision. As Neha Shah, Co-Founder and CEO, stated, "Red blood cells have been hiding in plain sight as a diagnostic tool for decades, and we are just beginning to unlock what they can tell us."